Empreses emergents
2021
ATG THERAPEUTICS SL Desenvolupem noves classes de fàrmacs i biomarcadors per prevenir la resistència terapèutica del càncer Avançar la nostra cartera de teràpies als assaigs clínics i millorar la vida dels afectats per la resistència terapèutica del càncer
Adreça
Avinguda de la Granvia de l’Hospitalet 199, 08908 L'Hospitalet de Llobregat, Espanya
Dades financeres
Propietat CERCA
L'Hospitalet de Llobregat, Spain
2004
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
Contacte del Centre CERCA
LT
Laia TravesetResponsable innovació
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)Altres accionistes públics catalans
Logotip
Àrees d'estat i deeptech
Estat de l'empresa i àrees de tecnologia profunda de l'empresaEstat de l'empresa
Àrea DeepTech
Informació sobre la spin-off
Descripció de l'empresa
The Angiotheragnostics (AtG) team has identified and validated a new therapeutic target to prevent anti-angiogenics resistance, as well as a plasma biomarker that selects patients that will benefit from the treatment. They are now in the early stages of developing this drug and biomarker kit, the first of its kind to target anti-angiogenics resistance.
AtG has identified two families of small molecules that inhibit this target protein, reducing its proliferation in cancer cell lines and impairing tumor growth after anti-angiogenic therapy fails.
AtG has identified two families of small molecules that inhibit this target protein, reducing its proliferation in cancer cell lines and impairing tumor growth after anti-angiogenic therapy fails.
Descripció del producte
Our findings:
Novel mechanism of action - Innovative anti-cancer therapeutic target
Drug candidate - New small molecule candidates
New biomarker - Patient selection technology
Technology
Angiotheragnostics’ technology is based on our unique ability to design and develop strategies that selectively target and eliminate cancer cells resistant to anti-angiogenic therapy
How it works
Determine plasma levels of RF-1 in metastatic kidney patients
Selection of patients with higher RF-1 levels
Treatment with RF-1 inhibitor
Novel mechanism of action - Innovative anti-cancer therapeutic target
Drug candidate - New small molecule candidates
New biomarker - Patient selection technology
Technology
Angiotheragnostics’ technology is based on our unique ability to design and develop strategies that selectively target and eliminate cancer cells resistant to anti-angiogenic therapy
How it works
Determine plasma levels of RF-1 in metastatic kidney patients
Selection of patients with higher RF-1 levels
Treatment with RF-1 inhibitor